This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
by Kinjel Shah
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
The Zacks Analyst Blog Highlights T-Mobile US, AstraZeneca and Comcast
by Zacks Equity Research
TMUS, AZN, and CMCSA show diverging paths as 5G gains, pipeline growth, and streaming resilience shape their outlooks.
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast
by Mark Vickery
TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
by Kinjel Shah
AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
by Zacks Equity Research
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
by Kinjel Shah
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What's Fueling Tempus AI's Explosive Sales Growth?
by Sridatri Sarkar
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last close.
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
by Kinjel Shah
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
by Moumi Mondal
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
by Kinjel Shah
SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer
by Zacks Equity Research
FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.